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Abstract: 18 
Following recent advances in nutrigenomics and nutrigenetics, as well as in view of the increasing 19 
use of nutraceuticals in combination with drug treatments, considerable attention is being directed 20 
to the composition, bioefficacy and release performance of dietary supplements. Moreover, the 21 
interest in the possibility of having such products tailored to meet specific needs is fast growing 22 
among costumers. To fulfill these emerging market trends, 3D printed capsular devices originally 23 
intended for conveyance and administration of drugs were proposed for delivery of dietary 24 
supplements. Being composed of separate inner compartments, such a device could yield 25 
customized combinations of substances, relevant doses and release kinetics. In particular, the aim of 26 
this work was to face early-stage industrial development of the processes involved in fabrication of 27 
nutraceutical capsules for oral pulsatile delivery. A pilot plant for extrusion of filaments based on 28 
pharmaceutical grade polymers and intended for 3D printing was set up, and studies aimed at 29 
demonstrating feasibility of fused deposition modeling in 3D printing of capsule shells according to 30 
Current Good Manufacturing Practices for dietary supplements were undertaken. In this respect, the 31 
stability of the starting material after hot-processing and of the resulting items was investigated, and 32 
compliance of elemental and microbiological contaminants, as well as of by-products, with internal 33 
specifications was assessed. Finally, operating charts highlighting critical process variables and 34 
parameters that would serve as indices of both intermediate and final product quality were 35 
developed. 36 
 37 
Keywords: fused deposition modeling, microextrusion, capsular device, pulsatile release, caffeine. 38 
  39 
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1. Introduction 40 
 41 
Innovative drug delivery systems (DDSs) in the form of functional containers have recently been 42 
proposed, wherein polymer coating barriers of traditional reservoir systems, manufactured by film-43 
coating or layering processes, have been replaced by capsule shells ready for filling. Such shells 44 
would be able to control the rate, time and/ or site of release based on their design and composition 45 
(1-4). As the capsular device can extemporaneously be filled with different formulations, it offers 46 
great flexibility and potential for customization, particularly in its recently described configuration 47 
including separate compartments (5). 48 
Starting from a variety of pharmaceutical grade polymers, single- and multi-compartment capsular 49 
devices with different release (immediate, prolonged and delayed/pulsatile) performance were 50 
fabricated by injection molding (IM) and fused deposition modeling (FDM) 3D printing (4-6). 51 
While IM could be exploited for large-scale production of a variety of capsule shells with pre-52 
determined release behavior, FDM holds promise as a prototyping tool and would also enable on-53 
demand fabrication of small batches of drug products designed to meet the needs of single patients 54 
(7-9). 55 
Given the recent advances in nutrigenomics and nutrigenetics, as well as the growing attention 56 
towards the use of dietary supplements in support of drug therapies, personalization is currently 57 
drawing interest not only in the area of pharmaceutics but also in the nutraceutical field, e.g. for 58 
modification of the type or amount of supplement intake over time or use of vegan and kosher 59 
ingredients (10-12). Furthermore, there is a fast-increasing awareness about the benefits that may 60 
arise from the application of modified release strategies to dietary supplements (13-14). To meet the 61 
demand for more and more sophisticated nutraceuticals, young companies or start-ups have lately 62 
been founded (e.g. Nootropics, Nootrobox, KalibrateV, Elysium, Ritual, Panaceutics). 63 
Based on such premises, the purpose of the present work was to assess the feasibility of the capsular 64 
device as a nutraceutical delivery platform starting from prototypes made on a laboratory scale and 65 
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accomplish early industrial development of the 3D printing fabrication process, which has never 66 
been faced before. Accordingly, stability of the starting materials after hot-processing and of the 67 
resulting items needed to be assessed, to rule out formation of any hazardous degradation product. 68 
In addition, the potential for industrialization of the first step involved in the fabrication of the 69 
capsular devices, consisting in hot melt extrusion (HME) of filaments based on pharmaceutical 70 
grade polymers and intended for FDM, was evaluated, and studies aimed at the development of all 71 
production stages, including 3D printing of capsule shells to be automatically filled in-process, were 72 
undertaken. In this respect, the construction of a pilot plant for capsule printing in agreement with 73 
Current Good Manufacturing Practices (CGMPs) for dietary supplements was finally approached 74 
by highlighting critical processing stages that may affect the product quality and by assaying the 75 
performance of printed prototypes with customizable design. 76 
 77 
2. Materials and Methods 78 
 79 
2.1. Materials 80 
Hydroxypropyl cellulose (HPC; Klucel™ LF, Ashland, US-MA; two different batches indicated as 81 
1 and 2); caffeine (ACEF, I); polylactic acid (PLA) filament (L-PLA natural, ø 1.75 mm; 82 
MakerBot® Industries, LLC, US-NY); blue and yellow dye-containing powder products ready for 83 
use (Kollicoat® IR Brilliant Blue and Kollicoat® IR yellow, BASF, D); deuterium oxide (Aldrich; 84 
99.9 % D); ethylene glycol (Aldrich, anhydrous, 99.8%, I); di-sodium hydrogen phosphate 85 
dodecahydrate (Merck KGaA, 99%, D); methanol (Sigma-Aldrich, ACS reagent, reg. ISO, reag. Ph. 86 
Eur., ≥ 99.8%, I); poly(ethylene glycol)/poly(ethylene oxide) (PSS Polymer standards service 87 
GmbH, D); sodium phosphate monobasic monohydrate (Aldrich, puriss. p.a., ACS reagent, ≥ 88 
99.0%, I); water (Aldrich, HPLC grade, I). 89 
 90 
2.2. Methods 91 
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2.2.1. Preparation and characterization of filaments 92 
Filaments were prepared by HME starting from HPC powder. 93 
- In-house prepared filaments (HMELab) - Filaments were obtained as reported in (6) starting from 94 
batch 1 of neat HPC powder (PD1) kept in an oven at 40 °C for 24 h prior to use. A twin-screw 95 
extruder (Haake™ MiniLab II, Thermo Scientific, US-WI) equipped with counter-rotating screws 96 
and a custom-made aluminum rod-shaped die (ø = 1.80 mm) was employed. The filament diameter 97 
was verified every 5 cm in length, and portions having diameter out of the 1.75 ± 0.05 mm range 98 
were discarded. 99 
- Industrially-manufactured filaments (HMEInd) - Filaments were also manufactured at Gimac’s 100 
facilities in Castronno (VA), Italy, starting from batch 2 of neat HPC powder (PD2) by means of a 101 
specially-assembled microextrusion system; 3 different batches were produced (HMEInd1, 102 
HMEInd2 and HMEInd3). Details on the equipment and process are reported and discussed within 103 
the Results and Discussion section. The obtained filaments were cut into pieces of 1 m in length and 104 
packed into moisture-protective bags in common use for nutraceuticals. After production, the 105 
filament diameter was checked every 30 cm in length using a digital caliper (Mitutoyo, J). 106 
Measurements were performed normally to the filament axis in two mutually perpendicular 107 
directions, and roundness index was calculated as the ratio between the diameters measured in the x 108 
and y axis. Mechanical properties of filaments were evaluated using an Instron 1185-5800R 109 
dynamometer (Instron, US-IL) equipped with a 10kN load cell. Commercially-available PLA 110 
filament was taken as a reference. Tensile tests were carried out on 200 mm long cylindrical 111 
samples (n = 3) with nominal diameter of 1.75 mm. The initial clamping distance, L0, was about 112 
100 mm and the crosshead speed was 1.25 mm/min. Applied displacement, L, and the relevant 113 
load, F, were measured, from which strain, = L/L0, and stress, = F/(R2), were estimated. 114 
From the resulting stress-strain curve, the Young modulus, E, i.e. the slope of the first linear part of 115 
the curve, was determined. Moreover, the peak stress to initial failure, i.e. the value of stress 116 
obtained at the first strain beyond which such a parameter started to decrease, was selected as an 117 
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index of the material strength (σ*). As an example, Figure 1 reports a typical curve for the PLA 118 
filament. Moreover, elemental (i.e. lead, arsenic, cadmium, mercury) and microbiological 119 
contamination was evaluated according to the relevant USP monographs [USP <2232> and 120 
<2023>] in a certified laboratory (Micro Quality Labs, Inc., US-CA) specialized in pharmaceutical, 121 
nutraceutical and cosmetic testing. 122 
 123 
2.2.2 Printing of capsular devices 124 
Capsular devices were 3D printed by FDM, starting from HPC filaments. 125 
- Laboratory-scale printed capsular devices (FDMLab) - 3D printing was performed by a MakerBot 126 
Replicator 2 (MakerBot® Industries, US-NY) starting from HMELab filaments as described in (6). 127 
- Industrially-fabricated capsular devices (FDMInd) - 3D printing was performed at Multiply Labs 128 
production site in San Francisco, US-CA, by a commercial 3D printer (Series 1 Pro, Type A 129 
Machines, US-CA) purposely modified, starting from HMEInd filaments. Computer-aided design 130 
(CAD) files were designed using an engineering 3D modeling software, saved in .stl format, 131 
imported to the 3D printer software and then converted in GCode instructions for the 3D printer. 132 
The printer trajectory and extrusion rates were improved to ensure the correct wall thickness, while 133 
minimizing printing defects such as gaps and over- or under-extruded sections. Details on the 134 
equipment and process are reported and discussed within the Results and Discussion section. 135 
 136 
2.2.3. Characterization of capsular devices 137 
Capsule parts were checked for weight (analytical balance BP211, Sartorius, D; n = 10) and 138 
thickness (MiniTest FH7200 equipped with FH4 probe, ø sphere = 1.5 mm, ElektroPhysik, D; n = 139 
10). Digital photographs (Nikon D70, Nikon, J) of samples were also acquired. 140 
The morphological changes undergone by capsular devices when exposed to aqueous fluids were 141 
evaluated by immersing two-compartment units, filled with approximately 25 mg of a blue and a 142 
yellow dye-containing formulation, respectively, in unstirred deionized water at the temperature of 143 
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37 ± 0.5 °C. Digital photographs were taken every 30 sec using a digital camera (GoPro Hero 144 
Session, US-CA). The opening time of each compartment was determined by visual inspection and 145 
defined as the time of first rupture of the hydrated shells, as highlighted by rapid dissolution of the 146 
dye inside the capsule compartment and its outward diffusion. 147 
The release performance of capsular devices (n = 6) having each compartment filled with 25 mg (cv 148 
≤ 2) of caffeine was evaluated according to a method previously developed (5). The assembled 149 
capsules were inserted into sinkers and tested using a modified USP38 three-position disintegration 150 
apparatus (Sotax, CH), wherein each basket-rack assembly moved at a 31 cycles/min rate in a 151 
separate vessel filled with 800 mL of distilled water at 37 ± 0.5 °C (15). Fluid samples were 152 
withdrawn at fixed time points and assayed spectrophotometrically (λ = 205 nm). By linear 153 
interpolation of release data immediately before and after the time point of interest, time to 10% 154 
release (t10%) was calculated. 155 
 156 
2.2.4 Thermal studies 157 
2.2.4.1 Differential Scanning Calorimetry (DSC) 158 
DSC analyses were performed by a Mettler Toledo DSC1 (Mettler Toledo, CH), weighing 5-10 mg 159 
of each sample in a standard 40 μL aluminum pan. An equal empty pan was used as the reference. 160 
In order to overcome any effect of their thermal history, specimens were heated from 25 °C to 250 161 
°C at 10 °C min-1, kept for 5 min at 250 °C, cooled to 25 °C at -10 °C min-1, left for 2 min at 25 °C 162 
and finally heated again to 250 °C at 10 °C min-1, under nitrogen flux. 163 
 164 
2.2.4.2 Thermal Gravimetric Analysis (TGA) 165 
TGA analyses were performed on 6 mg of neat HPC powder using Perkin-Elemer TGA 4000 166 
(Perkin Elmer, US-MA) under 20 mL/min nitrogen purge. A temperature ramp from 30 °C to 160 167 
°C at 20 °C/min was set followed by an isothermal analysis at 160 °C for 20 min. 168 
 169 
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2.2.5 Analyses of by-products 170 
2.2.5.1 Fourier-transform infrared spectroscopy (FT-IR) 171 
FT-IR spectra of powder, extruded filaments and 3D printed samples were acquired by a 100 172 
spectrophotometer (Perkin Elmer, US-MA) in the attenuated total reflection (ATR) mode, at a 173 
resolution of 4.0 cm-1 and 256 scans and in a 4000 and 400 cm-1 wavenumber range. A single-174 
bounce diamond crystal was used with an incidence angle of 45°. 175 
 176 
2.2.5.2 Proton Nuclear Magnetic Resonance (1H-NMR) 177 
1H-NMR spectra were collected at 25 °C using a Bruker 400 MHz spectrometer (Bruker, D) from 178 
samples prepared by dissolving 10 mg of powder, extruded filaments or 3D printed samples in 1 179 
cm3 of D2O. In order to detect by-products soluble in organic solvents, powder, extruded and 180 
printed samples were kept for 24 h at room temperature in methanol, and 1H-NMR analyses were 181 
performed on methanolic fractions dried under nitrogen flux and then solubilized in D2O. 182 
 183 
2.2.5.2 Gel Permeation Chromatography (GPC) 184 
GPC analysis was performed using a size exclusion chromatography (SEC) system consisting of a 185 
Waters 1515 isocratic HPLC pump (Waters, US-MA), a PlySep three-column set [(20-300)Da; 186 
(100-10000)Da; (3000-400000)Da] (Phenomenex, US-CA) and a refractive index (RI) detector 187 
(Knauer RI Detector 2300, Knauer, D). The flow rate and the injection volume were set at 0.35 188 
mL/min and 50 μL, respectively. 30 mg samples were dissolved in 1 mL of phosphate buffer pH 6.3 189 
(100 mM), and solutions were filtered (0.45 μm) before injection. Ethylene glycol was used as the 190 
internal reference in each analysis and data collected were normalized with respect to the main 191 
peak. Molecular weight data, i.e. number average molecular weight (Mn) and weight average 192 
molecular weight (Mw), were obtained using linear poly(ethylene glycol)/poly(ethylene oxide) as 193 
the calibration standard in the 62-490000 Da range. Molecular weight distribution (D) was also 194 
estimated from dispersity (Mw/Mn). 195 
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 196 
2.2.6 Rheological studies 197 
Viscosity of 5% w/w HPC solutions in distilled water obtained from powder and filament was 198 
measured using a HAAKE Viscotester C (Thermo Fisher Scientific, US-MA). The method 199 
employed was that described by the producer of Klucel™ LF, except for R4 spindle and 60 rpm 200 
rotational speed in that they enhanced the reproducibility of data (16). 201 
 202 
3. Results and discussion 203 
Based on the extensive experience gained on hot-processing of HPC and on its availability in 204 
different viscosity grades, which makes it a versatile main component for capsule shells intended 205 
for different release patterns (e.g. prompt release or pulsatile release after lag phases of programmed 206 
duration), such a polymer was identified as an advantageous raw material to start with for setting up 207 
a fabrication process compliant with Current Good Manufacturing Practices (CGMPs) for dietary 208 
supplements (17-19). 209 
In order to commercialize a dietary supplement based on the new delivery platform, the quality of 210 
the raw materials and intermediates, such as the polymeric filament undergoing 3D printing, has to 211 
be demonstrated, and fulfillment of all requirements of the final product needs to be ensured (20). In 212 
this respect, besides confirming the identity of raw materials, a number of other specifications are to 213 
be met, which should be assessed by relying on the certificate of analysis provided by a qualified 214 
supplier and also performing appropriate tests. Because neither extruded filaments based on HPC 215 
nor FDM-printed products based on such a polymer are currently available on the market, it was 216 
necessary to assess stability of the starting material to hot-processing.  217 
 218 
3.1. Assessment of HPC stability following laboratory-scale HME and FDM  219 
In the beginning, it was investigated whether any degradation phenomena would occur following 220 
the laboratory-scale processes. In particular, the thermal and rheological behavior of extruded 221 
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intermediates (i.e. filaments, HMELab) and printed capsules (FDMLab), as well as possible 222 
formation of by-products, were evaluated in comparison with the pharmaceutical-grade HPC 223 
powder selected (i.e. Klucel® LF powder batch 1, PD1), by a range of suitable techniques. DSC and 224 
TGA were exploited to study the thermal properties of samples, particularly in the temperature 225 
ranges to be used in HME and FDM processes. Moreover, micro- and macro-molecular changes 226 
possibly brought about by hot-processing, i.e. changes of molecular weights and molecular weight 227 
distribution of the polymer and formation of low-molecular weight compounds, were investigated 228 
by FT-IR, 1H-NMR and GPC. 229 
HPC powder was shown to lose approximately 2% of its initial mass when kept at 160 °C for 20 230 
min (TGA data not shown), which was ascribed to removal of adsorbed water. As expected, no 231 
water signal was observed in DSC curves relevant to the extruded filament, most likely due to the 232 
high temperature it was subjected to throughout manufacturing (Figure 2). With FDM products, 233 
fabricated at ambient conditions, water loss was still evident probably due to moisture uptake within 234 
processing (printing time ≈ 5 min). No other differences in DSC data of processed versus 235 
unprocessed specimens were highlighted, thus indicating that neither for HME nor for FDM the 236 
processing of the material affected the thermal properties of the samples. Major differences relevant 237 
to extruded and printed products with respect to the starting powder were not even found in either 238 
FT-IR and 1H-NMR spectra or 1H-NMR spectra from the methanolic fractions, in which less polar 239 
low molecular weight by-products might have partitioned (Figure 3). 240 
GPC curves and molecular weight data relevant to HPC powder, filaments and printed samples are 241 
reported in Figure 4 and Table 1, respectively. Two peaks relevant to HPC-based materials (i.e. 242 
peak 1 and 2) were highlighted, while the peak at about 4800 s refers to the internal reference used 243 
(i.e. ethylene glycol). The wide peak in the 2500-3500 s retention time range (peak 1) was observed 244 
both in the HPC powder and in the processed samples, which could be attributed to a broad 245 
molecular weight distribution of the polymer, also confirmed by relevant D values. However, the 246 
shape of such a peak may have resulted from aggregation phenomena. Peak 2, indicating the 247 
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presence of lower molecular weight components, was also detected in all specimens, thus ruling out 248 
the formation of by-products during the process. This GPC pattern (i.e. a wide peak at lower 249 
retention times and a small peak at higher times) was already described for HPC and attributed to 250 
the synthetic nature of the polymer, characterized by the presence of different macromolecular 251 
species with relatively higher or lower degree of hydroxylation (21). The presence of aggregates 252 
resulting from the same retention time region of higher molecular weight components was also 253 
investigated, and the relevant formation was demonstrated to be promoted by the experimental 254 
conditions. Peak 1 was the widest for PD1 among all samples, which may be associated with the 255 
highest extent of aggregation. 256 
The overall results support the possibility of using HPC for the manufacturing of filaments and 257 
printing of capsular devices under the experimental conditions used without causing major 258 
degradation phenomena. 259 
 260 
3.2 Development of a pilot plant for microextrusion of HPC filaments 261 
The issue of the lack of filaments ready for printing and consequent need for their large-scale 262 
production was subsequently addressed. An industrial partner specialized in microextrusion was 263 
involved in the development and construction of an extrusion plant for one-step production of 264 
filaments that could be compliant with regulatory requirements in force in the nutraceutical field. 265 
Microextrusion does not represent a simple scale-down of traditional HME being characterized by 266 
the ability i) to produce items having very complex geometry and narrow tolerances, ii) preserve the 267 
chemical properties of the starting materials and iii) process polymeric blends expected to perform 268 
according to their physical and chemical characteristics. Indeed, such a technique was already 269 
exploited for fabrication of devices intended for biomedical applications. Particularly, the feasibility 270 
of microextrusion in the production of tubes, filaments or porous wires to be composed into patches 271 
or scaffolds was evaluated, and critical aspects, such as their mechanical properties, the tolerances 272 
achieved and the potential degradation of the processed formulation, were dealt with (22-26). 273 
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The main constraints in the production of the HPC-based filaments were related to the utilization, 274 
for the equipment to be devised, of construction materials that may fulfill the requirements involved 275 
by the intended application. For instance, all components of the extruder should be inert and easily 276 
cleanable. Moreover, the strict dimensional tolerances of produced filaments should be met, while 277 
taking the need for setting up simple and cost-effective processes into proper account. The use of 278 
machineries and tools for pilot-scale trials, engineered and supplied by the industrial partner, was 279 
explored with the aim of preliminarily assessing the process feasibility, and any necessary 280 
modifications were step-by-step introduced. 281 
While HME is traditionally carried out starting from free-flowing pellets in order to ensure a 282 
constant output of material and, consequently, dimensional consistency of the resulting filament, the 283 
challenge in this specific instance was to deal with HPC in powder form, thus skipping the 284 
compounding phase that commonly precedes such an operation. The powder (Klucel® LF powder 285 
batch 2, PD2) was dried at 70 °C for 8 h to remove residual water before hot-processing. HME was 286 
performed horizontally by a microextrusion system (Figure 5) equipped with a thermoregulated 287 
hopper (internal volume 0.1 L), wherein HPC was kept at 30 °C and in continuous motion by an 288 
angled-palette stirrer (1 rpm) in a dried and nitrogen-protected environment. Under such conditions, 289 
caking phenomena (i.e. adhesion and cohesion of powder particles without effective feeding of the 290 
microextruder) were avoided, and starve-feeding of the barrel through a conical opening was carried 291 
out. Along the barrel, four distinct thermoregulation zones were defined and independently 292 
controlled by means of fluid-thermoregulated bushings, each covering in length approximately four 293 
flights of the inner screw. The geometry of the latter was purposely conceived to allow efficient 294 
conveying of the powder within the first part of the barrel and proper flow of the melt beyond. 295 
Particularly, the screw had 30 L/D length, and its first four flights were characterized by palette 296 
shape on the ridge and reduced diameter of the core in order to break powder aggregates while 297 
rotating. 298 
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At the end of the barrel an extrusion head was mounted. It terminated with a spinning opening 299 
having land length of 10 mm and diameter of 1.75 mm, corresponding to the nominal filament 300 
diameter. The extrusion head was provided with a heating element sunk into brass and enclosed in a 301 
heat-exchange jacket cooled by a circulating fluid (water). Moreover, it was designed to be 302 
especially compact in the longitudinal direction, i.e. the extrusion axis, as this made it easier to limit 303 
undesired temperature instabilities, which would involve changes in viscosity of the melt and, 304 
therefore, in the relevant flow as well as in the filament diameter. Continuous contact of the head 305 
with the heat-exchange jacket allowed thermal energy to be distributed in such a way as to yield a 306 
practically constant temperature profile at the inner surface of the cavity where the filament 307 
diameter was defined, thus avoiding flow alterations and uncontrolled surface texture. The 308 
possibility of strictly controlling the extrusion temperature was of utmost importance also 309 
considering the impact of such a parameter on the pressure developed by the melt according to its 310 
rheological characteristics (2). In particular, HPC viscosity was shown to decrease by increasing the 311 
temperature above 140 °C, but critical issues related to overheating were also highlighted. 312 
Accordingly, the operating temperature was studied by progressively raising it from 85 to 175 °C 313 
along the barrel, and decreasing it under 140 °C in its last zone as well as in the extrusion head. 314 
Indeed, by reducing the temperature at the end of the barrel, the viscosity of the melt was settled, 315 
and a constant pressure of about 300 bar was exerted against the 40 µm filter here positioned. Such 316 
a pressure turned out sufficient to maintain a constant rate of material output, thus helping attain 317 
consistency in the filament diameter. 318 
As traditional water cooling devices could not be employed because of water solubility of the 319 
polymer, the outgoing filament was initially cooled using pressurized air and then at room 320 
temperature only. While cooling, the extruded product was pulled by a purposely-built haul-off 321 
system having servocontrolled series of rollers coated with Food and Drug Administration (FDA)-322 
approved elastomer. In order to avoid deformation of the hauled filament, the mutual position of the 323 
pulling rollers was defined by means of mechanical parts having highly-sensitive pneumatic 324 
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regulation. The filament was trailed through two subsequent double-laser units (Zumbach 325 
Electronic S.r.l., I) measuring the diameter in two perpendicular directions (measurement frequency 326 
0.5 s), thus allowing possible ovalization to be highlighted, i.e. lack of correspondence between 327 
diameters measured in the x and y axis, respectively. The former laser unit was positioned close to 328 
the extrusion head, and the latter was located at the end of the cooling path to check the dimensional 329 
parameters of the final filament. 330 
By progressively setting up the operating conditions, filaments consistently meeting the established 331 
dimensional specifications, i.e. diameter of 1.75 ± 0.05 mm and roundness index in the 0.989-1.011 332 
range, could be attained (Table 2). Only the lowest pulling speed and force enabled by the haul-off 333 
system were employed, which turned out suitable for holding the outgoing filament, driving it 334 
through the laser units and counteracting possible dimensional changes, without causing its 335 
deformation or rupture. In particular, pulling speed was automatically adjusted in the 1.5 - 1.7 336 
m/min range to deal with possible over- and under-sizing (< 5% of nominal 1.75 mm diameter), 337 
based on the measurements performed by the former laser unit. 338 
Combined setup of extrusion and pulling parameters was meant to be automated on the basis of the 339 
filament dimensions in the final production-scale equipment, in which a winding machine could 340 
also be included. 341 
 342 
3.3 Assessment of quality specifications for industrially-manufactured HPC filaments 343 
Three different batches of filaments were prepared for validation purposes (i.e. HMEInd1, 344 
HMEInd2, HMEInd3) by the developed microextrusion plant. Because filaments as supplied would 345 
represent the starting material to be employed for fabrication of printed products, selected quality 346 
specifications needed to be established based on parameters that were identified as critical, and 347 
routine tests for ascertaining the relevant fulfillment had to be developed. The latter should be 348 
performed not only by the manufacturer of the filament in order to control its quality, but also by 349 
the dietary supplement producer in order to verify compliance with the certificate of analysis and 350 
15 
accept the incoming batch. Particularly, diameter, roundness, microbiological attributes and 351 
presence of by-products as well as elemental contaminants were identified as quality indices, and 352 
proper internal specifications thereof were defined (Table 3). The three validation batches turned 353 
out compliant. With respect to by-products, FT-IR, 1H-NMR, 1H-NMR from the methanolic extract 354 
and GPC analyses were initially performed on both the filaments and the starting powder. As the 355 
rheological behavior of a polymeric solution is known to depend on the molecular weight of the 356 
solute, aqueous solutions of HPC prepared from polymer powder and filaments were compared with 357 
each other in terms of viscosity in order to highlight major changes in length of the macromolecular 358 
chains. Viscosity of 5% w/w solutions, as measured according to HPC producer, turned out to be in 359 
the 75 - 115 cps range (producer specifications 75-150 cps) for samples prepared from both powder 360 
batch PD2 and filament, thus indicating that such a parameter would not be affected by any changes 361 
in the polymer molecular weight and ruling out major degradation phenomena taking place during 362 
extrusion. On account of the obtained results, compliance with internal specifications for by-363 
products was ascertain on the basis of FT-IR, 1H-NMR and viscosity measurements. 364 
 365 
3.4 Development of a scalable FDM plant for printing of HPC capsule shells 366 
The manufacturing of capsule shells was subsequently faced, and the setup of a FDM 3D printing 367 
process that could be compliant with current regulatory requirements was the focus of the further 368 
part of the work. First of all, the facility where the process was intended to be run was brought up to 369 
CGMPs for dietary supplements standards. A prototype printer was then designed, which could 370 
easily be disassembled and cleaned (Figure 6). Particularly, commercially available and purposely 371 
fabricated parts were combined for the printer construction, having all components that would come 372 
in contact with the filament/product, i.e. the build plate, the extruder assembly and the filament 373 
feeding system, made of 316L stainless steel or of FDA-compliant materials. The equipment was 374 
also conceived to be operator-safe by adding an outermost enclosure, so that it could not 375 
unintentionally be accessed while working. Issues of potential contamination from moving 376 
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mechanical parts were also faced. Indeed, the extruder assembly of the 3D printer was suspended 377 
above the build plate and attached to carriages sliding along linear guides (Figure 6, detail a). The 378 
carriages were actuated by stepper motors, which controlled the motion of a timing belt 379 
transmission. In such a system, the main source of particle generation was represented by frictions 380 
between the carriages and the linear guides, and between the timing belt and the pulleys. Moreover, 381 
because lubrication of the linear guides was needed, the motion of the carriages may have generated 382 
oil droplets. Therefore, having the moving mechanical parts located over the build plate, particles 383 
and oil droplets may have fallen onto the latter, thereby contaminating products in fabrication. This 384 
risk was circumvented by enclosing the sources of potential contamination in a shielding system 385 
that consisted in a rigid barrier, sealed on all sides except above the moving parts to allow access 386 
for maintenance. Particles could not escape from the open side, because the 3D printer was 387 
operating inside a clean room with downward laminar airflow, dragging contaminants towards the 388 
bottom of the containment barrier. 389 
The extruder assembly (Figure 6, detail b), intended to melt the filament and deposit it onto the part 390 
being formed, was also enclosed into an analogous particle containment system. With respect to the 391 
original Type A printer, it was extensively modified in order to ensure compliance with CGMP for 392 
dietary supplements. Indeed, not only were parts in contact with the filament constructed in 316L 393 
stainless steel instead of aluminum, but also the overall assembly was devised to easily be opened, 394 
as opposed to most commercially-available printers. Furthermore, the heating chamber and the 395 
nozzle of the extruder assembly were modified according to the polymer employed, e.g. in terms of 396 
nozzle length and position of the heating elements and of the thermocouple. Such modifications 397 
were aimed at avoiding both overheating and rapid changes in temperature, which had already been 398 
demonstrated critical in that they impact on HPC stability and cause undesired alterations in the 399 
melt viscosity (2). During laboratory-scale printing trials, in fact, nozzle clogging, material 400 
browning and lack of reproducibility in the deposited amounts were observed. The overall shielding 401 
17 
system and the extruder assembly were subjected to periodical inspection and cleaning as a part of 402 
the equipment standard maintenance. 403 
The printer feeding mechanism was adjusted based on the mechanical properties of the filament in 404 
use in order to exert lower stress onto the latter, thus leading to an efficient and constant loading of 405 
the material into the equipment as deformation was thereby prevented. When compared with the 406 
standard PLA filament commonly supplied along with commercially available printers, the HPC 407 
filament was indeed characterized by lower strength and stiffness (HPC: E = 1.19 GPa, cv 4.43; * 408 
= 9.94 MPa, cv 21.56; PLA: E = 2.64 GPa, cv 4.13; * = 43.41 MPa, cv 6.47). 409 
As regards the design and dimensions of the capsule shell, as well as the mode and accuracy of 410 
printing, helpful hints were derived from the experience already acquired (4,5). The dimensions of 411 
size 00 gelatin capsules were chosen as a reference to be mimicked because they were deemed to 412 
yield an acceptable balance between inner capacity and swallowing compliance (see sketches in 413 
Table 4). The capsule shell was composed of two hollow parts having same length and width, with 414 
nominal thickness of 400 and 800 µm, respectively, and of a middle joint part. The latter was 415 
composed of two hollow truncated cones connected at their larger bases through a disk. When 416 
assembled by partial overlapping of the hollow parts with the joint, the capsular device comprised 417 
two separated internal compartments intended to break up at successive time points (two-pulse 418 
release performance) as a function of their wall thickness. The design characteristics for the joint 419 
were specially conceived to impart mechanical resistance to the printed piece and ease insertion into 420 
the hollow parts so that tight closure of the system would be possible. The nominal wall thickness 421 
of the truncated cones was of 800 µm, which was achieved through deposition of two adjacent 422 
layers of material, by means of a 0.4 mm nozzle. In addition, the printing software was adjusted so 423 
that changes in the deposition direction during fabrication, which may lead to structural 424 
weaknesses, could be avoided. Prototypes of hollow and middle parts were thus printed in order to 425 
assess the feasibility of the capsular device (Figure 7 and Table 4). Although it would have been 426 
possible to attain higher resolution and thinner multilayered wall thicknesses by the use of nozzles 427 
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with smaller orifice diameter (e.g. 0.2 mm), this would have increased the overall process time, 428 
which would be critical in the prospect of large-scale production and commercialization. 429 
 430 
3.5 Evaluation of HPC capsular devices and assessment of quality specifications 431 
To check the effectiveness of the locking system and the opening mechanism of the capsular device, 432 
release tests of samples filled with either different dyes or caffeine were carried out under unstirred 433 
and stirred conditions. 434 
As expected, thickness consistency turned out to be a critical goal especially in the case of thinner 435 
hollow parts. Although printing accuracy could still be improved, changes undergone over time in 436 
unstirred water by a device containing different dye colors in each compartment showed the desired 437 
pattern: i) swellable/erodible behavior consistent with the nature of the starting material, with 438 
evidence of formation of a gel layer followed by dissolution of the polymer, and ii) opening based 439 
on occurrence of a first tear at the least thick area of each compartment (Figure 8). Air bubbles 440 
associated with leakage of the dye were seen where hollow parts were not superimposed on the 441 
joint, and the opening time was dependent on their wall thickness. Accordingly, capsular devices 442 
having both compartments filled with caffeine as a tracer supplement, tested under stirred 443 
conditions, exhibited a two-pulse release profile due to successive opening of the 400 and 800 µm 444 
thick compartments (t10% = 27.15 min ± 4.72 SD and 89.12 min ± 15.63 SD, for the thinner and 445 
thicker compartments, respectively). 446 
In addition to assessing the performance of the printed device, quality specifications also needed to 447 
be established. In particular, it was important to assess process temperature ranges that would not 448 
only allow consistent printed objects with tightly adhering layers to be achieved but also prevent 449 
any negative impact on HPC stability during the latter heating step. During the FDM process, HPC 450 
filaments (HMEInd) were progressively pulled out from a dryer, set at 40 °C, connected with the 451 
printer in order to avoid moisture adsorption. Batches consisting of 15 printed items, either joints or 452 
hollow parts, were fabricated requiring a maximum processing time of 12 min per capsule. 453 
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Preliminary printing trials were performed keeping the HPC filament within the heating chamber 454 
for 30 min at the temperatures of 175 °C or 200 °C, in order to study the effect of harsh conditions. 455 
FT-IR and 1H-NMR spectra of the fabricated parts showed degradation of the material maintained 456 
at the higher temperature only. After verifying that the temperature of 175 °C could be used, 457 
stability of units printed at 175 and 180 °C (i.e. FDMInd175 and FDMInd180) was investigated in 458 
view of 5 °C fluctuations that might occur within the heating chamber of the equipment. Major 459 
differences were neither observed when comparing the two sets of samples with each other, nor 460 
with the starting batch PD2 of HPC powder (Figure 9). 461 
Following the printing trials carried out to define design features of the capsular device and 462 
appropriate FDM process conditions, specifications needed to be established with respect to critical 463 
parameters that impact on product quality. As regards microbiological attributes, by-products and 464 
elemental contaminants, the same specifications as for the starting filament were applied to the 465 
printed items that turned out compliant, thus ruling out any impact of the process on those variables. 466 
Further internal specifications relevant to weight of capsule parts and wall thickness of hollow 467 
halves are to be set on the basis of opening and release performance, which would be derived from 468 
fabrication and evaluation of a sound number of batches of suitable size. Validation of all 469 
specifications should then be accomplished. 470 
 471 
4. Conclusions 472 
3D printed multi-compartment capsular systems, originally devised for personalization of dosage 473 
and delivery of drugs, were proposed for application to the nutraceutical field in response to a 474 
growing market trend that envisages more and more complex needs in terms of composition and 475 
release performance of dietary supplements. In this respect, caffeine was the first ingredient to be 476 
considered during early development of the nutraceutical delivery platform because of the highly 477 
inter-individually variable response it may elicit in terms of awakeness and attention based on body 478 
weight, age, tolerance and genetic polymorphism of users. Moreover, caffeine would greatly benefit 479 
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from a pulsatile release mode so that the onset of its effects may be scheduled throughout the day 480 
when mostly needed. 481 
In the prospect of commercializing capsular devices for customizable supplement delivery, 482 
production-scale manufacturing of HPC filaments intended for 3D printing was set up, and 483 
development of an industrially viable 3D printing process for two-compartment capsule shells was 484 
started. It was thereby possible to demonstrate the suitability of the produced filaments and 485 
fabricate prototype capsule parts meeting pre-set elemental, microbiological and by-product 486 
specifications. Manually filled and assembled capsular devices showed the desired two-pulse 487 
release of caffeine, in agreement with the swellable/erodible nature of the starting polymer. 488 
Overall, the research activity performed led to outline an HME operating chart highlighting critical 489 
process variables and parameters that would serve as indices of filament quality (Figure 10a). 490 
Moreover, the results from the present work supported feasibility of FDM in fabrication of capsule 491 
shells within an industrial environment according to CGMPs for dietary supplements. Particularly, a 492 
compliant FDM printer was designed and built up, and related operating as well as product quality 493 
parameters were established (Figure 10b). The development of a filling station to be coupled with 494 
the 3D printer is ongoing, which would enable on-demand production of small batches of capsules 495 
having customized composition characteristics (i.e. type, amount and release mode of dietary 496 
ingredients) in a single step, with the additional advantage to have some of the quality parameters 497 
monitored in real-time (e.g. weight and thickness). 498 
 499 
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Table 1: Molecular weight data obtained by GPC from PD1, HMELab and FDMLab. 
Table 2: Process parameters for the production of HPC filaments. 
Table 3: Internal quality specifications set for the filament. 
Table 4: Weight and thickness of hollow and middle parts of a two-compartment capsular device. 
Table Captions
Table 1: Molecular weight data obtained by GPC from PD1, HMELab and FDMLab. 
 Mn Mw D 
PD1 
peak 1 12000 63500 5.3 
peak 2 628 632 1.0 
HMELab 
peak 1 27500 111000 4.0 
peak 2 627 629 1.0 
FDMLab 
peak 1 27100 113500 4.2 
peak 2 662 675 1.0 
 
Table 1 revised
Table 2: Process parameters for the production of HPC filaments. 
Barrel temperature, °C T1, 90, T2 130, T3 170, T4 130 
Extrusion head temperature, °C 130 
Screw speed, rpm 26 
Cooling temperature, °C 10 
Pulling speed, m/min 1.6  
Pulling force, kgf 0.08 
 
Table 2 revised
Table 3: Internal quality specifications set for the filament. 
Quality parameters Specifications 
Diameter 1.75 ± 0.05 mm 
Roundness index 0.989-1.011  
Microbiological 
attributes 
Total aerobic microbial count < 103 cfu/g 
total combined yeast and mold 
count 
< 102 cfu/g 
E. Coli in 10 g absent 
Pseudomonas in 10 g absent 
S. Aureus in 10 g absent 
Salmonella/Shigella in 10 g absent 
Heavy metals  
Lead < 1 ppm 
Arsenic < 0.5 ppm 
Cadmium <0.3 ppm 
Mercury < 1 ppm 
By-products absent* 
*no significant differences in FT-IR and 1H-NMR spectra as well as in rheological 
data compared with the starting powder 
 
Table 3 revised
Table 4: Weight and thickness of hollow and middle parts of a two-compartment capsular device. 
 
Joint Hollow parts 
 
  
Thinner compartment Thicker compartment 
Weight, mg (cv) 163.40 (5.83) 130.98 (4.82) 208.72 (4.85) 
Wall thickness, 
µm (cv) 
a, 800* 802 (12)   
b, 800* 791 (14)   
a’, 400*  405 (18)  
b’, 800*  
 
814 (10) 
*nominal thickness, µm 
 
Table 4
Figure 1: Stress versus strain curve for a PLA filament. The linear range for Young Modulus (E) 
determination and the value of * are highlighted. 
Figure 2: DSC curves from PD1, HMELab and FDMLab. 
Figure 3: (a) FT-IR, (b) 1H-NMR and (c) 1H-NMR on the methanolic extract spectra from PD1, 
HMELab and FDMLab. 
Figure 4: GPC curves from PD1, HMELab and FDMLab. 
Figure 5: Schematic of the microextrusion system employed: comprehensive view and details 
relevant to (a) stirrer, (b) first four flights of the screw and (c) extrusion head. 
Figure 6: Schematic of the 3D printer employed: (left) comprehensive view and (right) details 
relevant to (a) gantry and (b) extruder assembly. 
Figure 7: Printed hollow and middle parts of a two-compartment capsular device. 
Figure 8: Photographs of a capsular device including two compartments of 400 and 800 µm wall 
thickness, filled with yellow and blue dye, respectively, taken at successive time points during 
immersion in unstirred water. 
Figure 9: (a) FT-IR and (b) 1H-NMR spectra from PD2, FDMInd175 and FDMInd180. 
Figure 10: Operating charts reporting critical process variables and product quality parameters 
relevant to (a) HME and (b) FDM (potential application to automated in-process capsule filling 
enclosed in the dotted frame). 
Figure Captions revised
Figure 1 Click here to download Figure Melocchi A. et al., Figure 1.tif 
Figure 2 revised Click here to download Figure Melocchi A. et al., Figure 2 revised.tif 
Figure 3 revised Click here to download Figure Melocchi A. et al., Figure 3
revised.tif
Figure 4 Click here to download Figure Melocchi A. et al., Figure 4.tif 
Figure 5 revised Click here to download Figure Melocchi A. et al., Figure 5 revised.tif 
Figure 6 revised Click here to download Figure Melocchi A. et al., Figure 6 revised.tif 
Figure 7 revised Click here to download Figure Melocchi A. et al., Figure 7 revised.tif 
Figure 8 revised Click here to download Figure Melocchi A. et al., Figure 8 revised.tif 
Figure 9 revised Click here to download Figure Melocchi A. et al., Figure 9
revised.tif
Figure 10 revised Click here to download Figure Melocchi A. et al., Figure 10 revised.tif 
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